The conference room at the Shanghai Institute of Pharmaceutical Research was a tired space. The walls were the colour of old tea, the carpet worn thin in the path between the door and the long laminate table. Fluorescent lights buzzed overhead at a frequency that made the fillings in your teeth ache. It was a room designed for budgets and compliance meetings, not for moments that altered the trajectory of human civilisation. But history, Lin Fan was learning, rarely had the courtesy to happen in impressive settings.
Dr. Chen Yong sat at the head of the table, his posture stiff with the particular wariness of a man who had been coasting toward retirement and had suddenly found himself answering to a twenty-six-year-old billionaire who asked very strange questions. Beside him, three senior researchers had assembled: a biochemist named Dr. Wu, a pharmacologist named Dr. Shen (no relation to the ER attending), and a clinical trials specialist named Dr. Patel, who was not the same Dr. Patel from the hospital but who shared the same quiet competence. All of them looked confused. All of them looked suspicious. All of them looked exactly like people who had been told that a universal antibiotic had materialised out of thin air.
Lin Fan stood at the head of the table, a slim folder in his hand. The golden phone was silent in his pocket. He had transferred the molecular specifications onto a standard laptop, stripped of any System-identifying metadata. What remained was a clean, professional document that looked exactly like what it was: a research dossier for a new pharmaceutical compound.
"I've called you here," Lin Fan began, "because I'm about to show you something that will transform this institute. It will also transform the global pharmaceutical industry. I need you to review it carefully and tell me honestly whether it's feasible to bring this compound to clinical trials within the next year."
He distributed printed copies of the dossier. The researchers took them with the reflexive politeness of people who had been handed things in meetings for decades. Dr. Wu, the biochemist, was the first to flip through the pages. His expression, initially neutral, began to shift. First came confusion. Then disbelief. Then something that might have been awe.
"This compound," Dr. Wu said slowly. "Where did you get this molecular structure?"
"I can't tell you that. What I can tell you is that it's real. The preliminary data—limited though it is—suggests it's effective against every gram-positive and gram-negative strain it's been tested against. Including MRSA, VRE, and multi-drug-resistant Pseudomonas."
"That's impossible," Dr. Shen the pharmacologist said flatly. "No compound is active against both gram-positive and gram-negative bacteria across the entire spectrum. The cellular membranes are too different. The resistance mechanisms are too varied. If this were possible, someone would have discovered it decades ago."
"Someone did," Lin Fan said quietly. "The question is whether we can manufacture it, test it, and bring it to market."
Dr. Chen Yong, who had been silent throughout, set down his copy of the dossier with the careful deliberation of someone handling a holy relic. "Mr. Lin. If this compound is real—if these preliminary results can be replicated—then you are holding the most valuable pharmaceutical patent in human history. The global antibiotics market is worth over forty billion US dollars annually. A universal antibiotic would capture a significant portion of that market, not to mention the humanitarian implications. Every hospital in the world would need this drug."
"I'm aware of the financial implications. I'm more interested in the humanitarian ones."
Dr. Wu was still staring at the molecular diagrams, his lips moving silently as he traced the chemical pathways. "This binding site," he said, pointing at a diagram. "It targets a protein in the bacterial cell wall that no other antibiotic targets. It's completely novel. If this works the way the data suggests, resistance would take decades to develop. It's not just a new antibiotic. It's a new class of antibiotics."
"How long to replicate the synthesis?" Lin Fan asked.
"In our current facilities? We're not equipped for novel synthesis at scale. We've been manufacturing generics for years. Our equipment is functional but outdated. We'd need to upgrade the lab, hire additional synthetic chemists, and establish a pilot production line. With sufficient funding—" He paused, calculating. "We could have the first synthesised batch within three months. Clinical trials would take another twelve to eighteen months, depending on regulatory pathways."
"And the regulatory pathways? What obstacles are we likely to face?"
Dr. Patel, the clinical trials specialist, spoke for the first time. Her voice was measured, precise. "The standard approval process for a new antibiotic in China requires three phases of clinical trials. Phase I for safety, Phase II for efficacy, Phase III for large-scale confirmation. Given the public health implications, we could apply for accelerated review with the National Medical Products Administration. But even accelerated review would take at least a year. And that's assuming the trial data is unambiguous."
"It will be." Lin Fan's voice was calm, certain. The God‑Level Emergency Medicine skill hummed beneath his thoughts, and while it was not a research skill, it gave him an instinctive understanding of the drug's therapeutic potential. "What about international approval? The FDA? The European Medicines Agency?"
Dr. Patel's expression tightened. "That's where the real obstacles will be. The American pharmaceutical industry is heavily invested in the existing antibiotic market. Companies like Pfizer, Merck, and Johnson & Johnson make billions of dollars annually from drugs that Linfloxacin would render obsolete. They will not welcome this compound. They will challenge it at every stage—patent litigation, regulatory scrutiny, negative press. They have deep relationships with the FDA and the EMA. We should expect a hostile reception."
"Then we'll need allies. Political allies. Medical allies. Public support." Lin Fan turned to Dr. Chen Yong. "I want a detailed feasibility report within two weeks. Budget for equipment upgrades, additional hiring, and clinical trial costs. Don't worry about the numbers—I'll fund whatever's necessary. But I need a realistic timeline and a clear picture of the obstacles."
"Understood." Dr. Chen Yong hesitated. "Mr. Lin, may I ask a question that's not strictly scientific?"
"Ask."
"Why are you doing this? Most people who acquire a patent of this magnitude would sell it to the highest bidder. They wouldn't try to develop it themselves, let alone prioritise humanitarian access over profit. What's your objective?"
Lin Fan looked around the table. The researchers—confused, suspicious, cautiously hopeful—were waiting for an answer. He thought about the patients he had treated in the emergency room. The homeless man whose infected wound had nearly cost him his arm. The elderly woman with pneumonia who had responded to nothing until he had intervened. The children in the paediatric ward, their immune systems fragile, their futures uncertain. He thought about Li Chuhan, who had wept over a seven-year-old girl named Mei, dead of leukaemia because the treatments that existed were not enough. He thought about the note from the safe, still on his nightstand, asking him to use what he had found well.
"My objective," he said, "is to save as many lives as possible. The money is a tool. The patent is a tool. This institute, and all of you, are tools in the best sense of that word—instruments for achieving something that matters. I didn't create this compound, but I have the resources to bring it to the world. That's what I intend to do. If you want to be part of that, I'll give you everything you need to succeed. If you'd rather work somewhere else, I'll write you a generous recommendation. But if you stay, understand that we're going to face opposition from some of the most powerful corporations on the planet. And we're going to win."
The silence that followed was long and thoughtful. Dr. Wu closed the dossier and looked at Lin Fan with an expression that was no longer suspicious. It was almost reverent.
"I've spent thirty years in pharmaceutical research," Dr. Wu said quietly. "Most of it has been tweaking existing compounds to extend patents for another few years. Incremental work. Safe work. I never thought I'd see something like this. If you're serious—if you're really going to develop this drug—then I'll stay. I'll work harder than I've ever worked."
"So will I," Dr. Patel said. "The clinical trial obstacles are significant, but not insurmountable. If we can gather a strong enough evidence base, even the FDA will have to take notice. Especially if there's public pressure."
"Public pressure can be generated," Lin Fan said. "I've been building networks. Medical networks. Political networks. Media networks. When the time comes, we'll have voices in every major country calling for this drug to be approved. But first, we need the data. So let's start there."
He stood, gathering his folder. "Dr. Wu, I want a synthesis plan on my desk by the end of the week. Dr. Patel, begin drafting the clinical trial protocols. Dr. Chen, coordinate the budget and the equipment upgrades. I'll be in touch daily. This is the most important project this institute has ever undertaken. Treat it accordingly."
---
That evening, Lin Fan sat alone in the villa, the golden phone on the counter beside a cold cup of tea. The sun had set, and the lake was a dark mirror reflecting the first pale stars. The heron had retreated to its roost somewhere in the reeds. The compound was quiet.
He was thinking about the universal antibiotic—the pill that could change everything. The System had called it a landmark dividend, a reward for the cumulative moral weight of his actions. But it was also a test. The pharmaceutical industry would fight him, and the fight would be long and brutal. He would need every ally he had. Zhan Bingxue's logistics network. Minister Gao's political protection. Su Xiaoyu's media influence. Li Chuhan's moral clarity. The researchers at the institute, who were only now beginning to believe that the impossible was possible.
And beyond the immediate battle, there was a larger question. The System had given him a universal antibiotic. What else was waiting in its silent architecture? The Civilization Tech Tree module, still locked, promised far more radical technologies—fusion energy, carbon capture, advanced AI. Each of those would face opposition even more intense than the pharmaceutical industry's resistance to Linfloxacin. He was not just building a company or a foundation. He was building an alternative to the existing world order. And the existing world order would not surrender without a fight.
The golden phone chimed softly—a single, quiet note.
`[The path ahead is difficult, but you are not unprepared. The skills you have acquired, the relationships you have built, and the resources you command are all tools for the work ahead. Trust yourself. Trust your allies. And remember: the compound interest of decency accrues even in the darkest moments.]`
He read the message and set the phone aside. Outside, the stars were sharp and clear in the winter sky. The lake was still. The villa was quiet, but it was not empty. It was filled with the weight of what he carried and the quiet, steady knowledge that he was not carrying it alone.
Tomorrow, Li Chuhan would come to the institute. He would show her the dossier, explain the drug, and offer her the role he had promised. And then the work of saving millions of lives would begin in earnest.
He finished his tea, washed the cup, and went to bed. The heron cried once across the lake, and then was silent. The world, for a moment, was at peace.